{
  "id": 16305249,
  "title": "Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial",
  "url": "https://urgent.news/2026/10/24/neoadjuvant-nivolumab-with-or-without-visugromab-in-muscle-invasive",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-24T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04740-9"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04740-9 As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladder cancer with the GDF-15-neutralizing antibody visugromab and nivolumab produced encouraging pathological complete response and radiographic…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}